- NRx Pharmaceuticals Inc NRXP has signed an agreement with Cardinal Health Inc CAH to provide third-party logistics and distribution of Zyesami upon the potential FDA Emergency Use Authorization (EUA) approval.
- In May, NRx applied for EUA to the FDA for Zyesami (aviptadil) for critical COVID-19 patients with respiratory failure.
- Cardinal Health Specialty Pharmaceutical Distribution will serve as the exclusive distributor for Zyesami.
- In July, NRx validated the first commercial formulation with better stability of Zyesami. NRx also said that it has "achieved a 30-to-50 fold increase" in the manufactured lot size of the drug.
- Also Read: Why NRx Pharma Stock Is Trading Higher In Mid Day Session Wednesday?
- Price Action: NRXP shares are up 5.19% at $13.58 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareContractsSmall CapMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
